Cerdulatinib is primarily used in the treatment of certain types of cancers, particularly those involving B-cell and T-cell malignancies. It functions as a dual inhibitor of SYK and JAK kinases, which are critical in the signaling pathways that promote cancer cell survival and proliferation. This makes it a potential therapeutic option for patients with relapsed or refractory hematologic cancers, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Its ability to target multiple pathways simultaneously offers a promising approach for overcoming resistance to single-target therapies. Clinical trials are ongoing to further evaluate its efficacy and safety in various cancer types.